Oxis Gains US Patent for Multiple Myeloma Drug Treatment

Oxis International (OTCQB:OXIS) announced the U.S. Patent and Trademark Office approved a patent for OXIS-4235 treating myeloma.
As quoted in the press release:

The USPTO also requires that products made or sold under the patent be marked with the statement “Patent No. 9,580,382.”
The patent clears the way for Oxis Biotech to begin the process of pursuing clinical trials for OXIS-4235. The drug is a P62-ZZ chemical inhibitor intended for use as a treatment for multiple myeloma. According to the American Cancer Society, more than 30,000 people are expected to be diagnosed with the disease this year and more than 12,000 are expected to die from it.
Dr. Sean Xie of Pittsburgh, Pa., developed the drug. The drug is intended to stop the growth of multiple myeloma cells without harming healthy cells. In addition to shrinking the tumors, the dual purpose drug is also intended to increase bone density, a second benefit of the technology.

Click here to read the full press release.

Source: www.accesswire.com